NCT02723955 2024-12-27
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
Phase 1 Completed
GlaxoSmithKline
M.D. Anderson Cancer Center
EMD Serono
EMD Serono
M.D. Anderson Cancer Center